{"altmetric_id":770791,"counts":{"readers":{"mendeley":8,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":2,"unique_users":["434213099950213","108310215980773"],"posts_count":2},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":9},"twitter":{"unique_users_count":5,"unique_users":["Transplant_Doc","SSBMT","Alaskar98","Myeloma_Doc","ymori117"],"posts_count":6}},"selected_quotes":["Brentuximab vedotin RIC Allo in hodgkin lymphoma","Brentuximab enables reduced-intensity allotransplant in patients with relapsed Hodgkin lymphoma. 1-year survival: 100%"],"citation":{"abstract":"Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed\/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed\/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27.8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT.","abstract_source":"pubmed","altmetric_jid":"4f6fa60e3cf058f610006cba","authors":["Chen R","Palmer JM","Thomas SH","Tsai NC","Farol L","Nademanee A","Forman SJ","Gopal AK","Robert Chen","Joycelynne M. Palmer","Sandra H. Thomas","Ni-Chun Tsai","Len Farol","Auayporn Nademanee","Stephen J. Forman","Ajay K. Gopal"],"doi":"10.1182\/blood-2012-03-418673","endpage":"6381","first_seen_on":"2012-05-31T18:39:32+00:00","funders":["nci"],"issns":["0006-4971","1528-0020"],"issue":"26","journal":"Blood","last_mentioned_on":1488820456,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22611160","http:\/\/dx.doi.org\/10.1182\/blood-2012-03-418673"],"pdf_url":"http:\/\/www.bloodjournal.org\/content\/bloodjournal\/119\/26\/6379.full.pdf","pmid":"22611160","pubdate":"2012-05-24T00:00:00+00:00","publisher":"American Society of Hematology","publisher_subjects":[{"name":"Cardiovascular Medicine And Haematology","scheme":"era"},{"name":"Clinical Sciences","scheme":"era"},{"name":"Paediatrics And Reproductive Medicine","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Immunology and Microbiology","Biochemistry, Genetics and Molecular Biology"],"startpage":"6379","subjects":["hematology"],"title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.","type":"article","volume":"119","mendeley_url":"http:\/\/www.mendeley.com\/research\/brentuximab-vedotin-enables-successful-reducedintensity-allogeneic-hematopoietic-cell-transplantatio-1"},"altmetric_score":{"score":5.85,"score_history":{"1y":3,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5.85},"context_for_score":{"all":{"total_number_of_other_articles":8317445,"mean":7.0084957256017,"rank":1465298,"this_scored_higher_than_pct":82,"this_scored_higher_than":6847374,"rank_type":"exact","sample_size":8317445,"percentile":82},"similar_age_3m":{"total_number_of_other_articles":95385,"mean":5.6184407657469,"rank":15721,"this_scored_higher_than_pct":83,"this_scored_higher_than":79606,"rank_type":"exact","sample_size":95385,"percentile":83},"this_journal":{"total_number_of_other_articles":9777,"mean":5.6773308101473,"rank":1746,"this_scored_higher_than_pct":81,"this_scored_higher_than":8014,"rank_type":"exact","sample_size":9777,"percentile":81},"similar_age_this_journal_3m":{"total_number_of_other_articles":120,"mean":3.1711260504202,"rank":16,"this_scored_higher_than_pct":86,"this_scored_higher_than":104,"rank_type":"exact","sample_size":120,"percentile":86}}},"demographics":{"poster_types":{"member_of_the_public":2,"researcher":2,"science_communicator":1},"users":{"twitter":{"cohorts":{"Scientists":2,"Science communicators (journalists, bloggers, editors)":1,"Members of the public":2}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Researcher":3,"Student  > Doctoral Student":1,"Student  > Postgraduate":1,"Other":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":7,"Agricultural and Biological Sciences":1}}},"geo":{"twitter":{"SA":1,"US":1,"JP":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/#!\/Transplant_Doc\/status\/208249858618953728","citation_ids":[770791],"posted_on":"2012-05-31T17:33:30+00:00","author":{"name":"Muzaffar Qazilbash","url":"http:\/\/faculty.mdanderson.org\/Muzaffar_Qazilbash\/Default.asp","image":"https:\/\/pbs.twimg.com\/profile_images\/1805143659\/Profile_compressed_pic-_020412_normal.jpg","description":"Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own","id_on_source":"Transplant_Doc","tweeter_id":"162587280","geo":{"lt":null,"ln":null},"followers":3410},"tweet_id":"208249858618953728"},{"url":"http:\/\/twitter.com\/SSBMT\/statuses\/208311506658525184","license":"datasift","rt":["Transplant_Doc"],"citation_ids":[770791],"posted_on":"2012-05-31T21:38:28+00:00","author":{"name":"SSBMT \u0627\u0644\u062e\u0644\u0627\u064a\u0627\u0627\u0644\u062c\u0630\u0639\u064a\u0629","url":"http:\/\/www.ssbmt.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1889730655\/SSBMT2_leaf_normal.jpg","description":"\u200f\u200f\u200f\u200f\u200fSaudi Society of Blood & Marrow  Transplantation established in 2008. #ssbmt #bmtsm \u0627\u0644\u062c\u0645\u0639\u064a\u0647 \u0627\u0644\u0633\u0639\u0648\u062f\u064a\u0647 \u0644\u0632\u0631\u0627\u0639\u0629 #\u0627\u0644\u062e\u0644\u0627\u064a\u0627_\u0627\u0644\u062c\u0630\u0639\u064a\u0647 . \u062a\u0623\u0633\u0633\u062a 2008.","id_on_source":"SSBMT","tweeter_id":"303173846","geo":{"lt":null,"ln":null},"followers":3842},"tweet_id":"208311506658525184"},{"url":"http:\/\/twitter.com\/Alaskar98\/statuses\/208314436388274177","license":"datasift","rt":["Transplant_Doc"],"citation_ids":[770791],"posted_on":"2012-05-31T21:50:06+00:00","author":{"name":"Alaskar\u062f.\u0623\u062d\u0645\u062f \u0627\u0644\u0639\u0633\u0643\u0631","url":"http:\/\/kaimrc.med.sa","image":"https:\/\/pbs.twimg.com\/profile_images\/774554731511513088\/ghZJ-8go_normal.jpg","description":"\u200f\u200f\u200fConsultant Hematologist \u0627\u0633\u062a\u0634\u0627\u0631\u064a \u0623\u0645\u0631\u0627\u0636 \u0648#\u0633\u0631\u0637\u0627\u0646_\u0627\u0644\u062f\u0645 \u0648\u0632\u0631\u0627\u0639\u0629 #\u0627\u0644\u062e\u0644\u0627\u064a\u0627_\u0627\u0644\u062c\u0630\u0639\u064a\u0647 \u060c \u0627\u0644\u0628\u0648\u0631\u062f \u0627\u0644\u0643\u0646\u062f\u064a \u0648\u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u060c \u0627\u0644\u0645\u062f\u064a\u0631 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644 #\u0643\u064a\u0645\u0627\u0631\u0643 #\u0627\u0644\u0623\u0628\u062d\u0627\u062b_\u0627\u0644\u0637\u0628\u064a\u0629 @KAIMRC_KSA","id_on_source":"Alaskar98","tweeter_id":"427642022","geo":{"lt":24.68773,"ln":46.72185,"country":"SA"},"followers":6728},"tweet_id":"208314436388274177"},{"url":"http:\/\/twitter.com\/Myeloma_Doc\/statuses\/210020741452808192","license":"datasift","rt":["Transplant_Doc"],"citation_ids":[770791],"posted_on":"2012-06-05T14:50:21+00:00","author":{"name":"Robert Z. Orlowski","url":"http:\/\/faculty.mdanderson.org\/robert_orlowski\/","image":"https:\/\/pbs.twimg.com\/profile_images\/1118389100\/-1_normal.jpg","description":"Director of Myeloma Section at MD Anderson Cancer Center; Translational researcher who hates myeloma. Tweets are my own. Retweets \u2260 endorsements.","id_on_source":"Myeloma_Doc","tweeter_id":"187354183","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":7390},"tweet_id":"210020741452808192"},{"url":"http:\/\/twitter.com\/SSBMT\/statuses\/272349394597203971","license":"public","citation_ids":[770791],"posted_on":"2012-11-24T14:42:10+00:00","author":{"name":"SSBMT \u0627\u0644\u062e\u0644\u0627\u064a\u0627\u0627\u0644\u062c\u0630\u0639\u064a\u0629","url":"http:\/\/www.ssbmt.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1889730655\/SSBMT2_leaf_normal.jpg","description":"\u200f\u200f\u200f\u200f\u200fSaudi Society of Blood & Marrow  Transplantation established in 2008. #ssbmt #bmtsm \u0627\u0644\u062c\u0645\u0639\u064a\u0647 \u0627\u0644\u0633\u0639\u0648\u062f\u064a\u0647 \u0644\u0632\u0631\u0627\u0639\u0629 #\u0627\u0644\u062e\u0644\u0627\u064a\u0627_\u0627\u0644\u062c\u0630\u0639\u064a\u0647 . \u062a\u0623\u0633\u0633\u062a 2008.","id_on_source":"SSBMT","tweeter_id":"303173846","geo":{"lt":null,"ln":null},"followers":3842},"tweet_id":"272349394597203971"},{"url":"http:\/\/twitter.com\/#!\/ymori117\/status\/218977914690088960","citation_ids":[770791],"posted_on":"2012-06-30T08:02:57+00:00","author":{"name":"\u68ee\u3000\u52c7\u4e00","url":"http:\/\/twilog.org\/ymori117","image":"https:\/\/pbs.twimg.com\/profile_images\/848199682329255936\/8L7dBR04_normal.jpg","description":"\u9577\u91ce\u770c\u3067\u8840\u6db2\u5185\u79d1\u533b\u3092\u3057\u3066\u3044\u307e\u3059","id_on_source":"ymori117","tweeter_id":"128218698","geo":{"lt":36.65139,"ln":138.18111,"country":"JP"},"followers":3001},"tweet_id":"218977914690088960"}],"facebook":[{"title":"Brentuximab vedotin enables successful reduced-intensi... [Blood. 2012] - PubMed - NCBI","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=465061323532057&id=434213099950213","citation_ids":[770791],"posted_on":"2012-11-24T14:44:48+00:00","summary":"Brentuximab vedotin & RIC Allo in hodgkin lymphoma http:\/\/t.co\/vC14JwPs","author":{"name":"Saudi Scientific Society of Blood and Marrow Transplantation","url":"https:\/\/www.facebook.com\/434213099950213","facebook_wall_name":"Saudi Scientific Society of Blood and Marrow Transplantation","image":"https:\/\/graph.facebook.com\/434213099950213\/picture","id_on_source":"434213099950213"}},{"title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantati","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=435030306531532&id=108310215980773","citation_ids":[770791],"posted_on":"2012-07-02T15:48:28+00:00","summary":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","author":{"name":"\u0627\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0644\u064a\u0628\u064a\u0629 \u0644\u0627\u0645\u0631\u0627\u0636 \u0627\u0644\u062f\u0645 \u0648\u0646\u0642\u0644 \u0627\u0644\u062f\u0645 LSHBT","url":"https:\/\/www.facebook.com\/108310215980773","facebook_wall_name":"\u0627\u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0644\u064a\u0628\u064a\u0629 \u0644\u0627\u0645\u0631\u0627\u0636 \u0627\u0644\u062f\u0645 \u0648\u0646\u0642\u0644 \u0627\u0644\u062f\u0645 LSHBT","image":"https:\/\/graph.facebook.com\/108310215980773\/picture","id_on_source":"108310215980773"}}],"policy":[{"title":"Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/ta462\/documents\/committee-papers","license":"public","citation_ids":[6779406,1517410,508332,2964024,15397336,6235475,9683320,21631742,1814084,2278733,23148704,23148709,1130241,3880132,5584526,23148726,21631741,1963338,13339693,13252927,6282134,23148752,23148755,5727666,428812,721559,6084711,23148776,784785,23148785,23148791,23148799,9708007,23148805,2959391,770791,3019759,107612,23148827,23148833,23148838,5374148,23148847,17993528,23148855,23148862,22998336,17990524,17957197,22643948,508333,23148887,23148894,210457,23148895,23148899,6423774,22768750,19492804,2416454,3806076,20547254,23148910,3832338,14861341,23148931,231203,23148943,23148949,23148957,4780979,20550295,23148972,12006374,17962002,23148985,541794,23148990,1145378,15781531,583130,7196227,23149002,2856416,5647163,6621193,23149006,3456805,3956838,502901,4783754,4684920,4687257],"posted_on":"2017-03-06T17:14:16+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta462\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-8bc7d102d58ee08edcbe45e4b3303e953d02c5a23f2fd231931a3dc94491f766.jpg"}}]}}